Clinical trials: Protein Deficiency
HIV Infections, HIV Seronegativity
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
The purpose of this study is to see whether an HIV vaccine, ALVAC vCP205, is safe and can prevent HIV infection. The vCP205 vaccine will be tested with another vaccine, gp160MN/LAI-2.
- Trial name
- NCT00004579
- Testing
- gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
To determine the safety of vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) in human volunteers; to evaluate the immunogenicity of this preparation in human volunteers.
- Trial name
- NCT00000968
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Child Nutrition Disorders
A Nutrition/Hygiene Education Program for the Prevention of Child Malnutrition in Rural Kenya
This study will determine if an education program about hygiene and child feeding practices, taught by local village community health workers, will improve child growth and decrease the prevalence of childhood malnutrition in a…
- Trial name
- NCT01679535
- Testing
- nutrition and hygiene education
- Where
- United States
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
HIV Infections, HIV Seronegativity
A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults
To evaluate the safety and tolerability of the Chiron vaccine human immunodeficiency virus (HIV) p24(25 or 50 micrograms)/MF59 in healthy HIV-1 seronegative adults.
- Trial name
- NCT00002204
- Testing
- HIV p24/MF59 Vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chiron Corporation
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
PRIMARY: To examine the safety and potential improvement in immune responses elicited by combining rsgp120/HIV-1MN with the adjuvant QS-21.
- Trial name
- NCT00001044
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients.
- Conditions
- Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation
- Trial name
- NCT06727669
- Where
- 5 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
HIV Infections
Safety and Immune Response to a Clade C DNA HIV Vaccine
The purpose of this study is to evaluate the safety and immune response to an HIV clade C DNA vaccine and to an MF59-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.
- Trial name
- HVTN111 (NCT02997969)
- Testing
- DNA-HIV-PT123 vaccine, Protein/MF59 vaccine
- Where
- 5 sites in South Africa, Tanzania and 1 more
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
- Trial name
- NCT00006327
- Testing
- MN rgp120/HIV-1 and A244 rgp120/HIV-1
- Where
- Thailand
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- VaxGen
HIV Infections
A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
Primary: To determine whether additional boosting with soluble recombinant gp160 vaccine (VaxSyn) after priming with a vaccinia-HIV envelope recombinant (HIVAC-1e) provides a significant advantage in the degree and duration of…
- Trial name
- NCT00000631
- Testing
- HIVAC-1e, gp160 Vaccine (MicroGeneSys)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hypertension, Hand Grip Strength
The Effect of an Oral Nutritional Supplement on the Nutritional and Health Outcomes of the Elderly
I am conducting this research to find out if a peanut based food that is ready to use would improve the nutritional and health outcomes of the elderly when they consume it daily for 12 weeks.
- Conditions
- Hypertension, Hand Grip Strength, Body Weight, Iron Deficiency
- Trial name
- NCT06773975
- Testing
- Oral nutritional supplementation
- Where
- Ghana
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Ghana
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
To evaluate the safety and immune response to vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) using an accelerated dosage schedule; to evaluate duration of antibody response and its relationship to the dose and…
- Trial name
- NCT00000957
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein
This Phase I study is directed at evaluating the safety profile (as a primary end-point) and the immunogenicity (as a secondary end-point) of the recombinant HIV-1 Tat vaccine in healthy, immunologically competent adult subjects…
- Trial name
- ISSP-001 (NCT00529698)
- Testing
- Biologically active recombinant Tat protein
- Where
- 4 sites in Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Istituto Superiore di Sanità
Protein Deficiency
Comparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method
The purpose of this research study is to compare the varying qualities of protein supplements utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) method and evaluating the clinical outcome related to protein…
- Trial name
- PDCAAS (NCT01399333)
- Testing
- Group 1 Meal Replacement, Group 2 Protein Supplement, Group 3
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Southeast Bariatrics, PA
Psychological Distress, Protein Deficiency
The Effect of Plasma Donation Frequency on Donor Health
This project is a randomized controlled non-inferiority study that aims to cover knowledge gaps about the composition and development of plasma proteins, inflammation markers and mental health in Norwegian, voluntary, and unpaid…
- Conditions
- Psychological Distress, Protein Deficiency, Inflammation
- Trial name
- NCT05179200
- Testing
- Plasmapheresis, Whole blood donation
- Where
- Norway
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sykehuset Innlandet HF
HIV Infections
Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
To determine if priming (giving the first vaccination) with a vaccinia recombinant (HIVAC-1e) provides a significant advantage in immunogenicity (production of antibodies) compared to priming with a soluble recombinant protein…
- Trial name
- NCT00000630
- Testing
- HIVAC-1e, gp160 Vaccine (MicroGeneSys)
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Deficiency
Effect of Fermented Maillard Reacted Whey Protein on Immune Function
To investigate the impact of supplementing fermented Maillard reacted whey protein (F-MRP) on natural killer (NK) cell activity, circulating cytokines and serum protein levels.
- Trial name
- NCT02895204
- Testing
- Fermented Maillard reacted whey protein (F-MRP)
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Estrogen Deficiency
Effects of Fermented Red Clover on Muscle Strength and Muscle Mass
The project is designed as a randomized controlled, double-blinded, cross-over trial, including 10 healthy postmenopausal women consuming fermented red clover extract or placebo twice daily over a two-week period.
- Trial name
- NCT04154306
- Testing
- Red clover
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Aarhus